Low Complement C4 Predicts Improvement of Kidney Function After Direct‐Acting Antiviral Therapy for Hepatitis C Virus
Direct‐acting antiviral therapies (DAAs) may improve kidney function and proteinuria in certain patients with hepatitis C infection (HCV) and chronic kidney disease (CKD). To improve our understanding of HCV‐mediated kidney dysfunction, we aimed to evaluate the baseline predictors of improvement in...
Main Authors: | Meghan E. Sise, Ian Strohbehn, Donald Chute, Kathleen E. Corey, Dahlene N. Fusco, Venkata S Sabbisetti, Sushrut S. Waikar, Raymond T. Chung |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Health/LWW
2020-08-01
|
Series: | Hepatology Communications |
Online Access: | https://doi.org/10.1002/hep4.1528 |
Similar Items
-
Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
by: Ming V Lin, et al.
Published: (2016-01-01) -
Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C–Viremic Donor to Uninfected Recipient Kidney Transplantation
by: Meghan E. Sise, et al.
Published: (2020-04-01) -
New treatment of hepatitis C (Direct Acting Antiviral)
by: Mohsen Akhondi-Meybodi
Published: (2019-10-01) -
Characterisation of Hepatitis C Virus antiviral resistance in the era of direct acting antivirals
by: Smith, D
Published: (2019) -
Mexican experience with direct-acting antivirals in the treatment of hepatitis C
by: J.L. Pérez Hernández, et al.
Published: (2020-09-01)